Cargando…

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of the tumor necrosis factor receptor (TNFR) family. Agonist antibodies to these co-stimulato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schaer, David A, Hirschhorn-Cymerman, Daniel, Wolchok, Jedd D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030310/ https://www.ncbi.nlm.nih.gov/pubmed/24855562 http://dx.doi.org/10.1186/2051-1426-2-7

Ejemplares similares

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Hiding the road signs that lead to tumor immunity
por: Schaer, David A., et al.
Publicado: (2011)

Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy
por: Bremer, Edwin
Publicado: (2013)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

The future of cancer immunotherapy: microenvironment-targeting combinations
por: Murciano-Goroff, Yonina R., et al.
Publicado: (2020)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
por: Cohen, Adam D., et al.
Publicado: (2010)

The delicate balance of melanoma immunotherapy
por: Gyorki, David E, et al.
Publicado: (2013)

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Tumor necrosis factor receptor-mediated signaling pathways
Publicado: (1994)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity
por: Avogadri, Francesca, et al.
Publicado: (2010)

Combination immunotherapy: a road map
por: Ott, Patrick A., et al.
Publicado: (2017)

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2009)

Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
por: Mercogliano, María Florencia, et al.
Publicado: (2021)

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
por: Budhu, Sadna, et al.
Publicado: (2021)

Tumor necrosis factor as a pharmacological target
por: Ghezzi, Pietro, et al.
Publicado: (2005)

Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope
por: Schaer, David A., et al.
Publicado: (2011)

Role of the Interaction of Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors 1 and 2 in Bone-Related Cells
por: Kitaura, Hideki, et al.
Publicado: (2022)

Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α
por: Corti, Angelo, et al.
Publicado: (2022)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B., et al.
Publicado: (2013)

Tumor Necrosis Factor Receptor 2 (TNFR2): An Emerging Target in Cancer Therapy
por: Medler, Juliane, et al.
Publicado: (2022)

Study of tumor necrosis factor receptor in the inflammatory bowel disease
por: Souza, Roberta Figueiroa, et al.
Publicado: (2023)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
por: Pagnini, Cristiano, et al.
Publicado: (2021)

Basic characterization of antibodies targeting receptors of the tumor necrosis factor receptor superfamily
por: Zaitseva, Olena, et al.
Publicado: (2023)

Opportunistic infections in patients treated with immunotherapy for cancer
por: Kyi, Chrisann, et al.
Publicado: (2014)

Tumor necrosis factor receptor I, II and tumor necrosis factor-α levels in patients with burns
por: Endo, S, et al.
Publicado: (2000)

Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2
por: Fischer, Roman, et al.
Publicado: (2017)

Self-antigen–specific CD8(+) T cell precursor frequency determines the quality of the antitumor immune response
por: Rizzuto, Gabrielle A., et al.
Publicado: (2009)

Tumor Targeted Nanocarriers for Immunotherapy
por: Baeza, Alejandro
Publicado: (2020)

Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history
por: Peña-Asensio, Julia, et al.
Publicado: (2020)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Improved Endpoints for Cancer Immunotherapy Trials
por: Hoos, Axel, et al.
Publicado: (2010)

Induction of tumoricidal function in CD4(+) T cells is associated with concomitant memory and terminally differentiated phenotype
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2012)

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_60o5e2qoimp0a19srrp5imh5ri